Get the Stockscreener App
24.46
0.49%
-0.115
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $24.46, with a volume of 17.32M.
It is down -0.49% in the last 24 hours and up +2.43% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$24.58
Open:
$24.71
24h Volume:
17.32M
Relative Volume:
0.41
Market Cap:
$139.09B
Revenue:
$62.46B
Net Income/Loss:
$7.88B
P/E Ratio:
17.73
EPS:
1.38
Net Cash Flow:
$11.22B
1W Performance:
-4.64%
1M Performance:
+2.43%
6M Performance:
-7.00%
1Y Performance:
-17.67%
1-Day Range:
$24.42
$24.78
1-Week Range:
$24.42
$25.63
52-Week Range:
$20.91
$31.54
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.46 | 146.57B | 62.46B | 7.88B | 11.22B | 1.38 |
|
LLY
Lilly Eli Co
|
770.49 | 709.79B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
164.16 | 379.41B | 90.63B | 22.66B | 18.57B | 9.35 |
|
ABBV
Abbvie Inc
|
188.92 | 344.45B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
114.67 | 244.38B | 53.22B | 12.86B | 14.85B | 6.39 |
|
NVO
Novo Nordisk Adr
|
64.30 | 315.52B | 43.59B | 15.04B | 10.74B | 3.3766 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Rx Rundown: Sarepta Therapeutics, Juul, Pfizer and more - Medical Marketing and Media
BMS, Pfizer take DTC route for blood thinner Eliquis - pharmaphorum
Bristol Myers, Pfizer to sell blood thinner Eliquis directly to US patients - Reuters
BMS/Pfizer To Sell Discounted Eliquis Direct – And Other Drugmakers May Follow Suit - insights.citeline.com
Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off - Benzinga
Pfizer (PFE) Expands Patient Access With Eliquis (Apixaban) Direct Purchase Program - simplywall.st
Pfizer’s EPIC-Peds Study: A Potential Game-Changer for Pediatric COVID-19 Treatment - TipRanks
Pfizer’s Phase 1 Study on PF-07941944: Key Insights for Investors - TipRanks
Pfizer’s Pediatric Leukemia Study: Implications for BESPONSA’s Market Potential - TipRanks
Bristol Myers, Pfizer to offer Eliquis at a discount for some patients - BioPharma Dive
Pfizer, Lilly spend big on telehealth contracts: Lawmaker report - Sherwood News
Major drugmakers offer big discount on blood thinner Eliquis - Fox Business
Bristol-Myers Squibb (BMY) and Pfizer (PFE) Stocks Jump on Eliquis Drug Discount - TipRanks
Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients - Reuters
Pfizer Inc.'s (NYSE:PFE) recent 3.7% pullback adds to one-year year losses, institutional owners may take drastic measures - Yahoo Finance
Lifestyle Drugs Market Future Business Opportunities - openPR.com
How Bristol Myers Squibb and Pfizer's Direct-to-Patient Eliquis Initiative is Reshaping Anticoagulant Access and Profitability - AInvest
Drugmakers to Sell Popular Blood Thinner Eliquis at 40% Discount - Bloomberg.com
BMS-Pfizer alliance to offer Eliquis at 40% discount to cash-paying patients - Investing.com Canada
Bristol Myers, Pfizer Slash Eliquis Price by 40% with New Direct-to-Patient Program for Top Blood Thinner - Stock Titan
Exclusive | Bristol-Myers and Pfizer to Offer Blockbuster Blood Thinner at Discount - The Wall Street Journal
Bristol Myers, Pfizer To Offer Blood Thinning Drug At Discount: Retail Chatter Around BMY Jump 60% In 24 Hours - Stocktwits
4 High-Yield Large-Caps With Dividend Risk and Opportunity in Focus - Investing.com
Pfizer’s Latest Clinical Study: A New Hope for Advanced Melanoma Treatment? - TipRanks
Pfizer’s INLYTA® Study Completion: Real-World Insights and Market Impact - TipRanks
Pfizer’s Hemophilia Study Completion: Market Implications and Insights - TipRanks
AbbVie and Pfizer’s Promising Study on Lung Cancer Treatment: A Market Game-Changer? - TipRanks
Pfizer’s BeneFIX Study Completion: Market Implications and Insights - TipRanks
Pfizer Subsidiary Recalls Bicillin L-A; South Dakota Department of Health Advises Caution - mykxlg.com
Jim Cramer Says Pfizer Needs a Catalyst - MSN
NYC Mayor Race: Mamdani Talks 'Intifada', Taxes in Grilling by Business Leaders - Bloomberg
Pfizer (PFE) Shares Cross 7% Yield Mark - Nasdaq
Japan discards 2.5m doses of expired COVID drugs from Pfizer, Merck - Nikkei Asia
How Will Pfizer's Oncology Drugs Perform in Q2 Earnings? - MSN
Pfizer Plummets 2.4%—Is Oncology's Growth Spree Over? - AInvest
Morningstar Reduces Moat Rating For Pfizer (PFE) To Narrow - Insider Monkey
Ex-Pfizer Doctor Tells Congress He Didn’t Delay Covid Shot Data - Bloomberg.com
Pfizer describes new STAT6 inhibitors - BioWorld MedTech
She helped launch Pfizer's COVID-19 vaccine in the depths of the pandemic. Now, she's planning her next act. - Business Insider
TD Cowen Adjusts Price Target on Pfizer to $30 From $28, Maintains Hold Rating - MarketScreener
Oxford BioDynamics shares jump 118% after Pfizer validates blood-based cancer biomarker technology - Proactive Investors
Pfizer (PFE) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Pfizer Faces $1 Billion IRA Reform Hit As Analysts Expect Flat 2025 Outlook - Benzinga
Pfizer’s Phase 3 Study on PF-06821497: A Potential Game-Changer in Prostate Cancer Treatment - TipRanks
Pfizer’s New Phase 3 Study: A Potential Game-Changer in Prostate Cancer Treatment? - TipRanks
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know - Yahoo Finance
Pfizer (PFE) Reports XTANDI Shows Life-Extending Benefits - Insider Monkey
Pfizer Earnings Preview: What to Expect - MSN
Pfizer's Legal Crossroads: Navigating Risks and Opportunities in Pharma Litigation - AInvest
Pfizer Inc. - Britannica
Pfizer’s Study on Rimegepant and Pregnancy: What Investors Need to Know - TipRanks
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.49%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):